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ABSTRACT
Aim To evaluate the long-term safety and effectiveness 
of lopinavir/ritonavir (LPV/r) in a population-based cohort 
of HIV-1-infected children.
Methods All children enrolled in the Swiss Mother 
and Child HIV Cohort Study, treated with LPV/r-based 
combination antiretroviral treatment (cART) between 
November 2000 and October 2008, were included.
Results 88 children (25 (28%) protease inhibitor 
(PI)-naive, 16 (18%) ART-naive) were analysed (251 
patient-years on LPV/r). After 48 weeks on LPV/r, 
70 children had a median (interquartile range (IQR)) 
decrease in HIV-1 viral load of 4.25 log (5.45–3.17; 
PI-naive, n=17) and 2.53 (3.68–1.38; PI-experienced, 
n=53). Median (IQR) increase in CD4 count was 429 
(203–593; PI-naive) and 177 (21–331; PI-experienced) 
cells/µl. These effects remained stable throughout 192 
weeks for 25 children. Treatment was stopped for viral 
rebound in seven and suspected toxicity in 12 children.
Conclusion Long-term treatment with LPV/r-based 
cART is safe and effective in HIV-1-infected children.
INTRODUCTION
Combination antiretroviral therapy (cART) sig-
niﬁ cantly reduces mortality in HIV-infected chil-
dren. One class of antiretroviral drug commonly 
used in cART are the protease inhibitors (PIs). 
These drugs are now mostly given with ritonavir, 
which inhibits their metabolism and boosts PI lev-
els. Recently, our group reported on the long-term 
safety and effectiveness of mainly unboosted 
PI-based cART in HIV-1-infected children enrolled 
in the Swiss Mother and Child HIV Cohort Study 
(MoCHiV).1 As boosted PIs have now become the 
standard of care, we have updated these analy-
ses focusing on children treated with lopinavir 
boosted with ritonavir (LPV/r).
PATIENTS AND METHODS
HIV-1-infected children living in Switzerland are 
prospectively followed by MoCHiV2 according to 
a common protocol and by use of structured data 
collection forms. Ethics approval was granted by 
the cantonal ethical committees of each partici-
pating centre and written informed consent of 
participants’ caregivers is obtained before inclu-
sion. As outlined elsewhere,1 children were seen 
before starting or changing cART and at weeks 4 
and 12, and every 12 weeks thereafter. The dos-
age of LPV/r was 300 mg/75 mg/m2 twice daily 
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for all children (adult dose for those ≥13 years of 
age). Adherence was assessed by self-declaration 
at each visit (ﬁ ve possible answers for the number 
of missed doses). Adverse events and abnormal 
laboratory results (DAIDS grade 3 or 4)3 during 
LPV/r treatment were considered as possible side 
effects, however treatment decisions were left to 
the treating physician’s assessment. Reasons for 
switching or stopping treatment were veriﬁ ed by 
chart review.
All children <18 years of age treated with LPV/r 
between November 2000 (paediatric approval) 
and October 2008 were included. Children were 
deﬁ ned as PI-naive if they had not received PI 
previously, and PI-experienced if they had been 
given PI as part of previous cART.
Plasma HIV-1 RNA loads were determined in 
real time using the Amplicor HIV Monitor kit 
(Roche, Basel, Switzerland) and CD4 cells using 
ﬂ ow cytometry. HIV-1 replication was considered 
suppressed if HIV-1 RNA was <50 copies/ml.
Data analysis
We analysed the ﬁ rst LPV/r treatment episode for 
each child, unless it lasted <30 days and was fol-
lowed by a subsequent longer episode, which was 
then examined instead. Baseline was deﬁ ned as the 
time of initiation of the examined LPV/r episode.
Immunological and virological responses were 
analysed at 6-monthly (24-week) intervals. 
Median (interquartile (IQR)) changes from base-
line and the percentage of patients with sup-
pressed HIV-1 replication were summarised at 
each time point. Patients who stopped LPV/r 
before the examined time point or had insufﬁ cient 
follow-up were either excluded from the analysis 
at that time point or, as a sensitivity analysis, we 
carried the last available measurement forward 
and imputed it for all subsequent time points (last 
observation carry forward).
In patients with detectable viral loads when 
starting LPV/r, we determined the time to com-
plete virological suppression (deﬁ ned as the ﬁ rst 
of two consecutive measurements of <50 copies/
ml) or time to stopping LPV/r without viral sup-
pression, whichever came ﬁ rst, using cumulative 
incidence functions. Viral rebound was deﬁ ned as 
the ﬁ rst of two consecutive HIV-1 RNA loads of 
>400 copies/ml or one HIV-1 RNA load of >400 
copies/ml plus a subsequent cessation of LPV/r 
within 91 days.
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Of 49 children with complete viral suppression (includ-
ing nine suppressed at baseline), viral rebound occurred in 
four PI-naive and three PI-experienced children during 124 
patient-years of follow-up (5.65 events per 100 patient-years). 
Median time to viral rebound was 2.18 (range 1.63–3.72 years; 
2.59 (2.17–3.72) in PI-naive and 1.85 (1.63–2.75) years in 
PI-experienced children).
After 48 weeks of LPV/r, median (IQR) increases in CD4 
counts and CD4 percentages were 429 (203–593) cells/μl and 
10% (3–18%) in PI-naive and 177 (21–331) cells/μl and 6% 
(2–9%) in PI-experienced patients.
Treatment interruptions and side effects
Forty two children (48%), including seven with viral rebound and 
12 with possible toxicity, stopped their LPV/r-based regimen dur-
ing follow-up. For the remaining 23 children, the reasons for stop-
ping treatment were: withdrawal from the cohort (n=7), patient’s 
or physician’s wish or decision (n=6 and n=4, respectively), struc-
tured treatment interruption (n=3) and unknown (n=3).
Among the 12 children with suspected toxicity, adverse 
events were: gastrointestinal in ﬁ ve (including liver and pan-
creas in one each), and related to fat redistribution, the nervous 
system, the endocrine system, cardiovascular disease, hyper-
sensitivity, blood count abnormality and unspeciﬁ ed in one 
each. Grade 3 or 4 laboratory abnormalities3 were documented 
in 27 children, but only three children stopped LPV/r (throm-
bocytopenia (11×109/l without recovery after treatment cessa-
tion), a liver enzyme elevation (aspartate aminotransferase 185 
IU/l) and an amylase elevation (870 IU/ml without elevation 
of serum lipase) in one each). Eleven of the 12 children with 
suspected toxicity restarted a LPV/r-based cART again after a 
median (IQR) interval of 0.98 (0.52–2.79) years. We observed 
no deaths on LPV/r.
DISCUSSION
The goal of the present study was to address the long-term 
safety and effectiveness of LPV/r-based cART in a population-
based cohort of HIV-1-infected children.
Our results show similar proportions of children with 
undetectable viral loads after 48 weeks as in the initial phase 
Statistical methods
The duration of ongoing LPV/r treatment episodes was esti-
mated using the Kaplan–Meier method. All analyses were per-
formed with R 2.8.0 (R Foundation for Statistical Computing, 
Vienna, Austria) and SAS 9.1 (SAS Institute, Cary, North 
Carolina, USA).
RESULTS
Our analysis included the ﬁ rst LPV/r treatment episode of 
84 children and the second (after a preceding episode of <30 
(9–17) days of four children (251 patient-years). Baseline char-
acteristics are summarised in table 1.
Twenty-ﬁ ve children (28%) were PI-naive including 16 (18%) 
who had never had any antiretroviral therapy. Seven PI-naive 
children had previously had other ART for a median time of 
1.6 (IQR 0.7–3.1) years, (zidovudine alone (n=3) or in combina-
tion with lamivudine (n=2), or non-PI based cART (n=2)).
Sixty-three (72%) children were PI-experienced (142 treat-
ment episodes; ritonavir (n=28), nelﬁ navir (n=17) or both 
(n=18)). Median time from the ﬁ rst PI-based regimen until 
treatment with LPV/r was 4.3 (IQR 3.2–6.1) years. Earlier PIs 
were most frequently combined with lamivudine/zidovudine 
(42 episodes) or lamivudine/stavudine (22 episodes).
The median duration of a LPV/r treatment episode was esti-
mated at 3.86 (95% CI 2.61 to 5.19) years.
Virological and immunological responses
This analysis was based on 70 (17 PI-naive, 53 PI-experienced) 
patients for whom baseline and at least one follow-up measure-
ment of HIV-1 RNA and CD4 cells was available (ﬁ gure 1).
Of 61 patients with detectable viral load when starting 
LPV/r, 40 (66%) achieved complete viral suppression (13/15 
(87%) PI-naive and 27/46 (59%) PI-experienced children). 
Median (IQR) time to full suppression was 180 (153–211) 
days in PI-naive and 152 (95–242) days in PI-experienced chil-
dren. Fifteen patients (25%; two PI-naive, 13 PI-experienced) 
stopped LPV/r before reaching complete viral suppression. 
After 48 weeks of LPV/r, median (IQR) decreases in viral 
load were 4.25 (5.45–3.17) in PI-naive and 2.53 (3.68–1.38) in 
PI-experienced patients.
Table 1 Baseline characteristics of 88 HIV-1-infected children receiving lopinavir boosted with ritonavir (LPV/r)
Characteristic*
Summary statistic†
Protease inhibitor (PI)-naive children (N=25) PI-experienced children (N=63) All children (N=88)
Age (years)    4.80 (2.86, 9.91)   11.63 (7.82, 14.47)     10.21 (6.36, 14.32)
Female gender 13 (52%) 38 (60%) 51 (58%)
Ethnicity
 White 3 (12%) 35 (56%) 38 (43%)
 Black 7 (28%) 19 (30%) 26 (30%)
 Hispano American 1 (4%) 4 (6%) 5 (6%)
 Asian 1 (4%) 2 (3%) 3 (3%)
 Unknown 13 (52%) 3 (5%) 16 (18%)
Route of HIV-1 infection
 Perinatal 17 (68%) 59 (94%) 76 (86%)
 Unknown 8 (32%) 4 (6%) 12 (14%)
Prior AIDS-defi ning condition 7 (28%) 28 (44%) 35 (44%)
CD4 cell count (cells/µl)‡ 402 (245, 826) 459 (289, 837) 434 (277, 859)
CD4 percentage‡ 20 (12, 28) 22 (16, 32) 22 (15, 30)
HIV-1 viral load (log10 RNA copies/ml)‡    5.41 (4.38, 5.67)   4.16 (2.70, 5.03)     4.34 (2.90, 5.26)
*Time-dependent covariates evaluated at the time of LPV/r initiation.
†Median (IQR) for continuous variables, n (%) for categorical variables.
‡CD4 cell count, CD4 percentage and HIV-1 viral load at LPV/r initiation (within −91/+30 days) were missing for 16, 19 and 14 children, respectively.
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was introduced into clinical use later than these other PIs, 
direct comparison is not feasible. Of note, median time to 
achieve viral suppression seems to be much longer in children 
than in adults.4
The proportion of children stopping cART (48%) for vari-
ous reasons was higher than reported elsewhere.5 However, 
treatment failure (n=7) and toxicity (n=12) accounted for only 
45% of this group. Laboratory abnormalities were associated 
I/II study of 100 children treated with LPV/r (69% in PI-naive 
and 54% in PI-experienced children). We also saw similar 
increases in CD4 cells (404 cells/μl in PI-naive and 284 cells/
μl in PI-experienced children). These virological and immuno-
logical effects observed in our cohort were maintained until 
week 192 in the 25 children who remained on LPV/r. These 
results with LPV/r compare favourably with ﬁ ndings from our 
earlier study with ritonavir or nelﬁ navir. However, as LPV/r 
Figure 1 Median (solid lines) and quartiles (dashed lines) of changes in CD4 cell count from baseline. The grey shaded area indicates the 
percentage of patients with suppressed HIV-1 viral load. Top panels: results based on actual HIV-1 viral load and CD4 cell counts at the respective 
week (n is the number of patients under follow-up and ongoing lopinavir boosted with ritonavir (LPV/r) therapy at the respective week). Bottom 
panels: results based on carry-forward of the last available HIV-1 viral load and CD4 cell count while on LPV/r for each patient. LOCF, last 
observation carry forward; LPV/r, lopinavir/ritonavir; PI, protease inhibitor.
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with only three children who stopped treatment. Most chil-
dren with suspected clinical toxicities re-started LPV/r-based 
regimens. Limitations of our study include the fact that adher-
ence was only assessed by self-declaration and viral resistance 
and drug levels were not routinely examined.
In conclusion, our data indicate that long-term treatment 
with LPV/r-based cART is well tolerated, safe and effective in 
HIV-1-infected children.
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